| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Are controlled trials of anticoagulation in children feasible?
|
Male, Christoph
|
|
|
7 |
3 |
p. e193-e194
|
article
|
| 2 |
Can virtual reality change the paediatric health-care experience?
|
Dunn, Amy L
|
|
|
7 |
3 |
p. e195
|
article
|
| 3 |
Catheter interventions: an unresolved clinical controversy
|
Avgerinos, Efthymios D
|
|
|
7 |
3 |
p. e189
|
article
|
| 4 |
Catheter interventions: an unresolved clinical controversy – Authors' reply
|
Notten, Pascale
|
|
|
7 |
3 |
p. e190
|
article
|
| 5 |
Clinical features and outcomes of patients with Shwachman-Diamond syndrome and myelodysplastic syndrome or acute myeloid leukaemia: a multicentre, retrospective, cohort study
|
Myers, Kasiani C
|
|
|
7 |
3 |
p. e238-e246
|
article
|
| 6 |
Comparison of international societal guidelines for the diagnosis of suspected pulmonary embolism during pregnancy
|
Cohen, Stuart L
|
|
|
7 |
3 |
p. e247-e258
|
article
|
| 7 |
Correction to Lancet Haematol 2020; 7: e100–11
|
|
|
|
7 |
3 |
p. e191
|
article
|
| 8 |
First-line dasatinib discontinuation in chronic myeloid leukaemia: another step towards an “operational cure”
|
Breccia, Massimo
|
|
|
7 |
3 |
p. e182-e183
|
article
|
| 9 |
Gene therapy 1·0 in haemophilia: effective and safe, but with many uncertainties
|
Makris, Michael
|
|
|
7 |
3 |
p. e186-e188
|
article
|
| 10 |
Idiopathic multicentric Castleman disease: bringing order to chaos
|
Leitch, Heather A
|
|
|
7 |
3 |
p. e180-e181
|
article
|
| 11 |
Imaging haemopoietic stem cells and microenvironment dynamics through transplantation
|
Williams, Kirsten M
|
|
|
7 |
3 |
p. e259-e269
|
article
|
| 12 |
Interferon-α: alternative first- or second-line therapeutic option for polycythaemia vera
|
Mascarenhas, John
|
|
|
7 |
3 |
p. e178-e179
|
article
|
| 13 |
Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study
|
Kiladjian, Jean-Jacques
|
|
|
7 |
3 |
p. e226-e237
|
article
|
| 14 |
Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials
|
van Rhee, Frits
|
|
|
7 |
3 |
p. e209-e217
|
article
|
| 15 |
Nursing impact on the CAR-T cell landscape
|
McDermott, Kathleen
|
|
|
7 |
3 |
p. e192
|
article
|
| 16 |
Plasma cell leukaemia presenting as flower-shaped plasma cells mimicking adult T-cell leukaemia or lymphoma
|
Shibusawa, Motoharu
|
|
|
7 |
3 |
p. e270
|
article
|
| 17 |
Polycythaemia vera, ruxolitinib, and hydroxyurea: where do we go now?
|
Spivak, Jerry L
|
|
|
7 |
3 |
p. e184-e185
|
article
|
| 18 |
Rare diseases: not so out of the ordinary
|
The Lancet Haematology,
|
|
|
7 |
3 |
p. e177
|
article
|
| 19 |
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study
|
Gisslinger, Heinz
|
|
|
7 |
3 |
p. e196-e208
|
article
|
| 20 |
Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial
|
Kimura, Shinya
|
|
|
7 |
3 |
p. e218-e225
|
article
|
Journal description